XBRANE.STSTOHealthcare · Biotechnology

Xbrane Biopharma AB (publ)

$11.00-3.93%($-0.45)

TickerSpark Score

73/100

Solid

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XBRANE.ST research report →

52-Week Range17% of range

Low $5.42

Current $11.00

High $38.10

Companywww.xbrane.com

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma.

CEO: Martin Amark
IPO: 2016
Employees: 65
HQ: Solna, SE

Price Chart

-67.16% · this period

Valuation

Market Cap: $133.92M
P/E: 2.14
P/S: 1.75
P/B: 0.41
EV/EBITDA: -2.20
Div Yield: 0.00%

Profitability

Gross Margin: 45.95%
Op Margin: -83.61%
Net Margin: 138.67%
ROE: 20.36%
ROIC: -10.53%

Growth & Income

Revenue: $152.35M · -23.32%
Net Income: $127.24M · 147.80%
EPS: $0.08 · 100.30%
Op Income: $-31,099,000
FCF YoY: -34.80%

Performance & Tape

52W High: $38.10
52W Low: $5.42
50D MA: $8.41
200D MA: $15.14
Beta: 0.89
Avg Volume: 66.73K

Get TickerSpark's AI analysis on XBRANE.ST

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime